Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment ...

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...

After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

This acquisition expands Sage’s offerings in repair services, which it says bolsters its existing ITAD services.

Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.

TD Cowen analyst Ritu Baral has maintained their neutral stance on SAGE stock, giving a Hold rating on October 17. Ritu Baral has given his ...

Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple ...

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...

The Sage Group develops and sells accounting and finance software for small and mid-sized businesses. Click here to read an ...